Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models

Abnormalities in brains of Alzheimer's disease (AD) patients are thought to start long before the first clinical symptoms emerge. The identification of affected individuals at this ‘preclinical AD’ stage relies on biomarkers such as decreased levels of the amyloid‐β peptide (Aβ) in the cerebrospinal fluid (CSF) and positive amyloid positron emission tomography scans. However, there is little information on the longitudinal dynamics of CSF biomarkers, especially in the earliest disease stages when therapeutic interventions are likely most effective. To this end, we have studied CSF Aβ changes in three Aβ precursor protein transgenic mouse models, focusing our analysis on the initial Aβ deposition, which differs significantly among the models studied. Remarkably, while we confirmed the CSF Aβ decrease during the extended course of brain Aβ deposition, a 20–30% increase in CSF Aβ40 and Aβ42 was found around the time of the first Aβ plaque appearance in all models. The biphasic nature of this observed biomarker changes stresses the need for longitudinal biomarker studies in the clinical setting and the search for new ‘preclinical AD’ biomarkers at even earlier disease stages, by using both mice and human samples. Ultimately, our findings may open new perspectives in identifying subjects at risk for AD significantly earlier, and in improving the stratification of patients for preventive treatment strategies.

[1]  C. Zuurbier,et al.  Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure? , 2015, Respiratory Research.

[2]  Reisa A. Sperling,et al.  Preclinical Alzheimer’s Disease , 2014 .

[3]  Philip S. Insel,et al.  Emerging β-amyloid pathology and accelerated cortical atrophy. , 2014, JAMA neurology.

[4]  P. Gil-Gregorio,et al.  Preclinical Alzheimer's disease , 2014 .

[5]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[6]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[7]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[8]  A. Fagan,et al.  Preclinical Alzheimer's disease criteria , 2013, The Lancet Neurology.

[9]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[10]  Leslie M. Shaw,et al.  Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI , 2013, Acta Neuropathologica.

[11]  Tammie L. S. Benzinger,et al.  Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers , 2013, Science Translational Medicine.

[12]  A. Fagan,et al.  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Alzheimer's & Dementia.

[13]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[14]  Alberto Lleó,et al.  Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease , 2012, Acta Neuropathologica.

[15]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[16]  O. Lopez,et al.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study , 2012, Acta Neuropathologica.

[17]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[18]  D. Holtzman,et al.  Mapping the Road Forward in Alzheimer’s Disease , 2011, Science Translational Medicine.

[19]  D. Holtzman,et al.  Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation , 2011, The Journal of Neuroscience.

[20]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[21]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[22]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[23]  T. V. Van Dooren,et al.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model , 2010, International journal of Alzheimer's disease.

[24]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[25]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[26]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[27]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[28]  M. Stoeckli,et al.  Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.

[29]  G. Ratcliff,et al.  Preclinical Alzheimer disease , 2004, Neurology.

[30]  B. Hyman,et al.  Beta-secretase activity increases with aging in human, monkey, and mouse brain. , 2004, The American journal of pathology.

[31]  M. Staufenbiel,et al.  Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid , 2002 .

[32]  S. Hirai,et al.  The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently , 2001, Neurobiology of Aging.

[33]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[34]  H. Vanderstichele,et al.  Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1 , 2000, The Journal of Neuroscience.

[35]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[37]  Sanfeliu,et al.  [15 years later]. , 1993, Revista de enfermeria.

[38]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[39]  R. Panush Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis , 2011 .

[40]  M. Staufenbiel,et al.  Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. , 2002, Journal of neurochemistry.

[41]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  S. Hirai,et al.  The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. , 2001, Neurobiology of Aging.

[43]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[44]  the original work is properly cited. , 2022 .